PTC Therapeutics, Inc. Deferred Income Tax Expense (Benefit)
PTC Therapeutics, Inc. (PTCT) reported Deferred Income Tax Expense (Benefit) of -$10.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-05-07
- PTC Therapeutics, Inc. deferred income tax expense (benefit) for the quarter ending 2026-03-31 was -$10.00K, a 600.00% decline year-over-year.
- PTC Therapeutics, Inc. deferred income tax expense (benefit) for the quarter ending 2025-12-31 was $1.00K.
- PTC Therapeutics, Inc. deferred income tax expense (benefit) for the quarter ending 2025-03-31 was $2.00K.
- PTC Therapeutics, Inc. deferred income tax expense (benefit) for the quarter ending 2024-12-31 was -$55.91M, a 1505.13% decline year-over-year.
- PTC Therapeutics, Inc. deferred income tax expense (benefit) for fiscal 2025 was -$3.00K.
- PTC Therapeutics, Inc. deferred income tax expense (benefit) for fiscal 2024 was -$55.91M.
- PTC Therapeutics, Inc. deferred income tax expense (benefit) for fiscal 2023 was -$46.93M.
- PTC Therapeutics, Inc. deferred income tax expense (benefit) for fiscal 2022 was -$34.28M, a 9191.78% decline from fiscal 2021.
| Period end | Deferred Income Tax Expense (Benefit) 1 month | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|---|
| 2026-03-31 | -$10.00K 10-Q · filed 2026-05-07 | -$9.00K derived: sum of 2 quarters · filed 2026-05-07 | |||
| 2025-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$3.00K 10-K · filed 2026-02-19 | |||
| 2025-09-30 | -$4.00K 10-Q · filed 2025-11-04 | ||||
| 2025-03-31 | $2.00K 10-Q · filed 2026-05-07 | -$55.91M derived: sum of 2 quarters · filed 2026-05-07 | -$55.91M derived: sum of 3 quarters · filed 2026-05-07 | -$55.91M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | -$55.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$55.91M derived: sum of 2 quarters · filed 2026-02-19 | -$55.91M derived: sum of 3 quarters · filed 2026-02-19 | -$55.91M 10-K · filed 2026-02-19 | |
| 2024-09-30 | -$3.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$1.00K derived: sum of 2 quarters · filed 2025-11-04 | -$2.00K 10-Q · filed 2025-11-04 | $3.98M derived: sum of 4 quarters · filed 2026-02-19 | |
| 2024-06-30 | $2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $1.00K 10-Q · filed 2025-08-07 | $3.98M derived: sum of 3 quarters · filed 2026-02-19 | $3.98M derived: sum of 4 quarters · filed 2026-02-19 | |
| 2024-03-31 | -$1.00K 10-Q · filed 2025-05-06 | $3.98M derived: sum of 2 quarters · filed 2026-02-19 | $3.98M derived: sum of 3 quarters · filed 2026-02-19 | -$46.93M derived: sum of 4 quarters · filed 2026-02-19 | |
| 2023-12-31 | $3.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $3.98M derived: sum of 2 quarters · filed 2026-02-19 | -$46.93M derived: sum of 3 quarters · filed 2026-02-19 | -$46.93M 10-K · filed 2026-02-19 | |
| 2023-09-30 | -$2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$50.91M derived: sum of 2 quarters · filed 2024-11-07 | -$50.91M 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | -$50.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$50.91M 10-Q · filed 2024-08-08 | |||
| 2023-05-31 | -$50.90M 10-Q · filed 2023-10-26 | ||||
| 2023-03-31 | -$4.00K 10-Q · filed 2024-04-25 | ||||
| 2022-12-31 | -$34.28M 10-K · filed 2025-02-27 | ||||
| 2021-12-31 | $377.00K 10-K · filed 2024-02-29 | ||||
| 2020-12-31 | $5.87M 10-K · filed 2023-02-21 | ||||
| 2019-12-31 | $8.83M 10-K · filed 2022-02-22 | ||||
| 2018-12-31 | $0.00 10-K · filed 2020-03-02 | ||||
| 2018-06-30 | $0.00 10-Q · filed 2018-08-07 | ||||
| 2017-12-31 | $199.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $199.00K derived: sum of 2 quarters · filed 2020-03-02 | $199.00K 10-K · filed 2020-03-02 | ||
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $0.00 10-Q · filed 2017-11-02 | |||
| 2017-06-30 | $0.00 10-Q · filed 2017-08-09 | ||||
| 2016-12-31 | $23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $45.00K derived: sum of 2 quarters · filed 2019-03-01 | -$199.00K 10-K · filed 2019-03-01 | ||
| 2016-09-30 | $22.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | -$222.00K 10-Q · filed 2017-11-02 | |||
| 2016-06-30 | -$244.00K 10-Q · filed 2017-08-09 | ||||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-06 | $0.00 10-K · filed 2018-03-06 | |||
| 2015-09-30 | $0.00 10-Q · filed 2016-11-03 | ||||
| 2014-12-31 | $0.00 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |